REZOLUTE INC (RZLT)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
Rezolute is a clinical-stage biotech company developing novel therapeutics for metabolic and inflammatory diseases.
What REZOLUTE INC does
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and inflammatory disorders. The company is advancing drug candidates through preclinical and clinical development phases, with R&D spending of ~$39M-$40M annually (9-month periods). The company maintains a lean operating structure with minimal assets and is funding operations through cash reserves and equity issuances.
Themes: ["clinical-stage biotech","metabolic diseases","inflammatory disorders","drug development"]
Fundamentals
- Price$5.13 as of 2026-07-09 close
- Market cap$494M as of 2026-07-10
- 1-year return-2.8% as of 2026-07-09 close
- ROE-58.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.58 as of 2026-07-10
Key risks (from latest filing)
["The company is pre-revenue and dependent on continued capital raises to fund ongoing R&D; cash and marketable securities of ~$120M may fund operations for limited period","Clinical development is inherently uncertain; failure to advance candidates through trials or obtain regulatory approval would materially impact prospects","Equity dilution from warrant exercises and ongoing financing activities reduces shareholder value"]
Competitors & peers
- Amgen (AMGN)
- Eli Lilly (LLY)
- Novo Nordisk (NVO)
- Viking Therapeutics
- Viking Therapeutics (VKING)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.